Investors

Event Calendar

 

Upcoming Events

Annual General Meeting: Thursday 27 June, 2024

Venue: TBC // Registration Deadline: Thursday 13 June 2024
Read more


    Past Events

    ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

    October 16, 2019

    Read more

    ObsEva to participate in Cantor Global Healthcare Conference October 2-4 2019

    October 4, 2019

    Read more

    ObsEva SA to present at Wedbush PacGrow Healthcare Conference – click ‘Read More’ below for webcast info

    August 14, 2019

    Read more
    1 14 15 16 17 18 32

    General Meetings

    ObsEva Annual General Meeting 2019

    May 8, 2019

    Read more

    ObsEva Annual General Meeting 2018

    May 9, 2018

    Read more
    1 2 3 4
     
     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue